TG Therapeutics, Inc. $TGTX Shares Sold by Blue Trust Inc.

Blue Trust Inc. decreased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 29.0% in the 2nd quarter, Holdings Channel reports. The firm owned 1,507 shares of the biopharmaceutical company’s stock after selling 616 shares during the quarter. Blue Trust Inc.’s holdings in TG Therapeutics were worth $54,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its stake in shares of TG Therapeutics by 54.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock valued at $898,000 after purchasing an additional 8,338 shares during the period. New York State Teachers Retirement System lifted its stake in shares of TG Therapeutics by 175.0% in the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company’s stock valued at $4,746,000 after purchasing an additional 76,600 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in shares of TG Therapeutics in the first quarter valued at about $226,000. GAMMA Investing LLC lifted its stake in shares of TG Therapeutics by 77.7% in the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 1,986 shares during the period. Finally, Strs Ohio acquired a new stake in shares of TG Therapeutics in the first quarter valued at about $785,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TGTX shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a research report on Thursday, July 10th. B. Riley lifted their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Finally, HC Wainwright began coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 target price for the company. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $49.00.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $34.67 on Friday. The company has a market cap of $5.50 billion, a PE ratio of 93.70 and a beta of 1.97. TG Therapeutics, Inc. has a 12 month low of $22.61 and a 12 month high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The company has a 50-day simple moving average of $32.18 and a 200-day simple moving average of $35.04.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million for the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business’s quarterly revenue was up 92.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.